Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Burton Brodsky

Obstetrics & Gynecology Sylvania, OH Medical Doctor

NPI 1164412078 CMS profile 189106

5308 Harroun Rd Ste 175, Sylvania, OH 43560

Open in the dashboard

General payments

$202,303

262 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Burton Brodsky of Sylvania, OH is reported in the CMS Open Payments database as having received $202,303 across 262 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $36 2
2023 General $76,112 96
2022 General $41,131 36
2021 General $18,658 30
2020 General $6,216 15
2019 General $60,149 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Burton Brodsky
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Burton Brodsky were reported at $0. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Burton Brodsky Obstetrics & Gynecology median Middle half National median
2019 $60,149 $172 $62–$391 $163
2020 $6,216 $94 $36–$222 $114
2021 $18,658 $136 $42–$369 $132
2022 $41,131 $160 $50–$433 $149
2023 $76,112 $169 $56–$423 $160
2024 $36 $152 $50–$371 $164
2025 $0 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Myriad Women's Health, Inc. $76,027 91 payments
  2. AbbVie, Inc. $72,424 86 payments
  3. Intuitive Surgical, Inc. $38,969 30 payments
  4. Myriad Genetic Laboratories, Inc. $11,740 7 payments
  5. Minerva Surgical, Inc $2,223 5 payments
  6. Gynesonics, Inc. $238 5 payments
  7. Boston Scientific Corporation $174 6 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $109 7 payments
  9. Hologic, LLC $72 4 payments
  10. Allergan Inc. $68 4 payments
  11. Other $261 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Honoraria $79,700 30 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $69,563 34 payments
  3. Education $36,000 9 payments
  4. Travel and Lodging $10,173 50 payments
  5. Food and Beverage $5,367 138 payments
  6. Consulting Fee $1,500 1 payment
Products named General payments · program years 2019–2024
  1. myRisk Oncology $76,027 91 payments
  2. Orilissa Endocrinology $57,664 63 payments
  3. Da Vinci Surgical System $38,969 30 payments
  4. myRisk Germline Dna Sequencing Hereditary Cancer And Rearrangement Analysis $11,740 7 payments
  5. ORILISSA Womens Health $10,474 11 payments
  6. ORIAHNN $5,814 10 payments
  7. Endometrial Ablation System (Device) $2,223 5 payments
  8. SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM $219 4 payments
  9. LO LOESTRIN FE $123 8 payments
  10. Kyleena $83 5 payments
  11. Other $892 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Median for Obstetrics & Gynecology: 65

Drug cost

$7,830

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

100%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 15 $7,830

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$1,687

Medicare's payments for the services billed

Medicare patients

13

Average age 61

Services billed

23

13 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Atrial fibrillation 0%
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

262 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record